Real-world impact on monthly glucose-lowering medication cost, HbA1c, weight, and polytherapy after initiating a GLP-1 receptor agonist
Authors:
- Tayla N. RoseTRTayla N. Rose
- Michelle L. JacobsMJMichelle L. Jacobs
- Debra J. ReidDRDebra J. Reid
- Carla J. BouwmeesterCBCarla J. Bouwmeester
- Michael P. ConleyMCMichael P. Conley
- Borna FatehiBFBorna Fatehi
- Thomas M. MattaTMThomas M. Matta
- Judith T. BarrJBJudith T. Barr
- 1 January 2020
- journal article
- research article
- Published by Elsevier in Journal of the American Pharmacists Association
- Vol. 60 (1) , 31-38.e1
Abstract
No abstract availableKeywords
This publication has 27 references indexed in Scilit:
- Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trialThe Lancet, 2014
- Efficacy and Safety of Dulaglutide Added Onto Pioglitazone and Metformin Versus Exenatide in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-1)Diabetes Care, 2014
- The INITIATOR study: pilot data on real-world clinical and economic outcomes in US patients with type 2 diabetes initiating injectable therapy.Advances in Therapy, 2013
- Patient perspectives on once‐weekly medications for diabetesDiabetes, Obesity and Metabolism, 2010
- Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trialDiabetologia, 2009
- Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)The Lancet, 2009
- Efficacy and Safety of the Human Glucagon-Like Peptide-1 Analog Liraglutide in Combination With Metformin and Thiazolidinedione in Patients With Type 2 Diabetes (LEAD-4 Met+TZD)Diabetes Care, 2009
- Liraglutide, a once‐daily human GLP‐1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD‐1 SU)Diabetic Medicine, 2009
- Efficacy and Safety Comparison of Liraglutide, Glimepiride, and Placebo, All in Combination With Metformin, in Type 2 DiabetesDiabetes Care, 2009
- Development and Validation of the Medication Regimen Complexity IndexAnnals of Pharmacotherapy, 2004